PLX (Protalix BioTherapeutics) Cyclically Adjusted PB Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLX Protalix BioTherapeutics Inc PLX
54 GF Score
Price $2.34
GF Value $2.21
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Protalix BioTherapeutics  (AMEX:PLX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Protalix BioTherapeutics Cyclically Adjusted PB Ratio Related Terms


Protalix BioTherapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Protalix BioTherapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protalix BioTherapeutics Cyclically Adjusted PB Ratio Chart

Protalix BioTherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Protalix BioTherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PLX vs GLSI, DTIL, NERV: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Protalix BioTherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Cyclically Adjusted PB Ratio falls into.


PLX
54GF Score
Protalix BioTherapeutics Inc PLX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protalix BioTherapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Protalix BioTherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Protalix BioTherapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.886/333.9520*333.9520
=0.886

Current CPI (Jun. 2026) = 333.9520.

Protalix BioTherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 -1.511 241.428 -2.090
201612 -0.802 241.432 -1.109
201703 -5.475 243.801 -7.500
201706 -1.601 244.955 -2.183
201709 -1.948 246.819 -2.636
201712 -2.049 246.524 -2.776
201803 -2.709 249.554 -3.625
201806 -3.345 251.989 -4.433
201809 -4.383 252.439 -5.798
201812 -3.564 251.233 -4.737
201903 -4.034 254.202 -5.300
201906 -4.548 256.143 -5.930
201909 -4.775 256.759 -6.211
201912 -4.739 256.974 -6.159
202003 -0.952 258.115 -1.232
202006 -1.072 257.797 -1.389
202009 -0.999 260.280 -1.282
202012 -0.778 260.474 -0.997
202103 0.320 264.877 0.403
202106 0.084 271.696 0.103
202109 0.005 274.310 0.006
202112 -0.132 278.802 -0.158
202203 -0.162 287.504 -0.188
202206 -0.203 296.311 -0.229
202209 -0.230 296.808 -0.259
202212 -0.198 296.797 -0.223
202303 0.016 301.836 0.018
202306 0.545 305.109 0.597
202309 0.524 307.789 0.569
202312 0.460 306.746 0.501
202403 0.408 312.332 0.436
202406 0.390 314.175 0.415
202409 0.441 315.301 0.467
202412 0.570 315.605 0.603
202503 0.579 319.799 0.605
202506 0.626 322.561 0.648
202509 0.659 324.800 0.678
202512 0.600 324.054 0.618
202603 0.834 330.213 0.843
202606 0.886 333.952 0.886

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Protalix BioTherapeutics (PLX) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of $2.34 is trading 5.9% above its estimated GF Value™ of $2.21. GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.

Key valuation signals for PLX:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $2.21 vs. price of $2.34 (5.9% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Protalix BioTherapeutics Business Description

Other Exchanges PBDA:Germany
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score

Get the complete analysis for PLX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price
$2.21
GF Value